Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic

Mayo Clin Proc. 2020 Nov;95(11):2467-2486. doi: 10.1016/j.mayocp.2020.08.030. Epub 2020 Aug 31.

Abstract

A higher risk of thrombosis has been described as a prominent feature of coronavirus disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis risk, prognostic implications, and anticoagulation effects in COVID-19. We included 37 studies from 4070 unique citations. Meta-analysis was performed when feasible. Coagulopathy and thrombotic events were frequent among patients with COVID-19 and further increased in those with more severe forms of the disease. We also present guidance on the prevention and management of thrombosis from a multidisciplinary panel of specialists from Mayo Clinic. The current certainty of evidence is generally very low and continues to evolve.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Anticoagulants / therapeutic use*
  • COVID-19 / complications
  • COVID-19 / epidemiology
  • COVID-19 Drug Treatment*
  • Humans
  • Minnesota
  • Practice Guidelines as Topic*
  • SARS-CoV-2*
  • Thrombosis / etiology
  • Thrombosis / prevention & control*

Substances

  • Anticoagulants